glp 1 antagonist side effects Managing of GLP-1 Receptor Agonists – Transformation Weight Control The expanding role of GLP-1

The unexpected shift towards phentermine, a lower-cost alternative at approximately $5 per month, emerges as a pragmatic response to the host of issues surrounding fulfillment of prescriptions for Wegovy including shortages, supply issues, the expiration of manufacturer coupons, and insurance coverage limitations which impact the accessibility of GLP-1 agonists

And the domains of potential benefit extend well beyond what most people associate with either therapy

[8] [22] In December 2024, the FDA revised the indication for tirzepatide (as Zepbound) to include the treatment of moderate to severe obstructive sleep apnea

For trainees and clinician-scientists, this is a reminder that therapeutic innovation and health economics are inseparable